Differential proteomics identifies PDIA3 as a novel chemoprevention target in human colon cancer cells

Molecular Carcinogenesis

Volumn 53, Issue S1, 2014, Pages

  Ménoret, Antoine ^a   Drew, David A ^a   Miyamoto, Shingo ^a   Nakanishi, Masako ^a   Vella, Anthony T ^a   Rosenberg, Daniel W ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Chemoprevention; Colon cancer; PDIA3; Proteomics; Resveratrol

Indexed keywords

CHEMOPREVENTION; COLON CANCER; PDIA3; PROTEOMICS; RESVERATROL;

ANTICARCINOGENIC AGENTS; BLOTTING, WESTERN; COLONIC NEOPLASMS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOPRECIPITATION; PROTEIN DISULFIDE-ISOMERASES; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; STILBENES; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84894442893     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.21986     Document Type: Article

References (68)

1. Rajamanickam S, Agarwal R. Natural products and colon cancer: Current status and future prospects. Drug Dev Res 2008; 69:460-471.
2. Meyskens FL, Jr., McLaren CE, Pelot D, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: A randomized placebo-controlled, double-blind trial. Cancer Prev Res (PhilaPa) 2008; 1:32-38.
3. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006; 355:873-884.
4. Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006; 355:885-895.
5. Cole BF, Baron JA, Sandler RS, et al. Folic acid for the prevention of colorectal adenomas: A randomized clinical trial. JAMA 2007; 297:2351-2359.
6. Nakanishi M, Menoret A, Tanaka T, et al. Selective PGE(2) suppression inhibits colon carcinogenesis and modifies local mucosal immunity. Cancer Prev Res (Phila) 4:1198-1208.
7. Telang NT, Li G, Katdare M. Prevention of early-onset familial/hereditary colon cancer: New models and mechanistic biomarkers (review). Int J Oncol 2006; 28:1523-1529.
8. Alessandro R, Belluco C, Kohn EC. Proteomic approaches in colon cancer: Promising tools for new cancer markers and drug target discovery. Clin Colorectal Cancer 2005; 4:396-402.
9. Yao Y, Jia XY, Tian HY, et al. Comparative proteomic analysis of colon cancer cells in response to oxaliplatin treatment. Biochim Biophys Acta 2009; 1794:1433-1440.
10. Ward DG, Nyangoma S, Joy H, et al. Proteomic profiling of urine for the detection of colon cancer. Proteome Sci 2008; 6:19.
11. Ruginis T, Taglia L, Matusiak D, Lee BS, Benya RV. Consequence of gastrin-releasing peptide receptor activation in a human colon cancer cell line: A proteomic approach. J Proteome Res 2006; 5:1460-1468.
12. Nakanishi M, Menoret A, Belinsky GS, et al. Utilizing endoscopic technology to reveal real-time proteomic alterations in response to chemoprevention. Proteomics Clin Appl 2007; 1:1660-1666.
13. Gonzalez-Sarrias A, Gromek S, Niesen D, Seeram NP, Henry GE. Resveratrol oligomers isolated from carex species inhibit growth of human colon tumorigenic cells mediated by cell cycle arrest. J Agric Food Chem 2011; 59:8632-8638.
14. Sengottuvelan M, Nalini N. Dietary supplementation of resveratrol suppresses colonic tumour incidence in 1, 2-dimethylhydrazine-treated rats by modulating biotransforming enzymes and aberrant crypt foci development. Br J Nutr 2006; 96:145-153.
15. Tessitore L, Davit A, Sarotto I, Caderni G. Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21(CIP) expression. Carcinogenesis 2000; 21:1619-1622.
16. Kineman BD, Au A, Paiva NL, Kaiser MS, Brummer EC, Birt DF. Transgenic alfalfa that accumulates piceid (trans-resveratrol-3-O-beta-D-glucopyranoside) requires the presence of beta-glucosidase to inhibit the formation of aberrant crypt foci in the colon of CF-1 mice. Nutr Cancer 2007; 58:66-74.
17. Cui X, Jin Y, Hofseth AB, et al. Resveratrol suppresses colitis and colon cancer associated with colitis. Cancer Prev Res (Phila) 2010; 3:549-559.
18. Schneider Y, Duranton B, Gosse F, Schleiffer R, Seiler N, Raul F. Resveratrol inhibits intestinal tumorigenesis and modulates host-defense-related gene expression in an animal model of human familial adenomatous polyposis. Nutr Cancer 2001; 39:102-107.
19. Sale S, Tunstall RG, Ruparelia KC, Potter GA, Steward WP, Gescher AJ. Comparison of the effects of the chemopreventive agent resveratrol and its synthetic analog trans 3, 4, 5, 4′-tetramethoxystilbene (DMU-212) on adenoma development in the Apc(Min+) mouse and cyclooxygenase-2 in human-derived colon cancer cells. Int J Cancer 2005; 115:194-201.
20. Ziegler CC, Rainwater L, Whelan J, McEntee MF. Dietary resveratrol does not affect intestinal tumorigenesis in Apc(Min/+) mice. J Nutr 2004; 134:5-10.
21. Weng YL, Liao HF, Li AF, Chang JC, Chiou RY. Oral administration of resveratrol in suppression of pulmonary metastasis of BALB/c mice challenged with CT26 colorectal adenocarcinoma cells. Mol Nutr Food Res 2010; 54:259-267.
22. Patel KR, Brown VA, Jones DJ, et al. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res 2010; 70:7392-7399.
23. Patel KR, Scott E, Brown VA, Gescher AJ, Steward WP, Brown K. Clinical trials of resveratrol. Ann N Y Acad Sci 2011; 1215:161-169.
24. Vang O, Ahmad N, Baile CA, et al. What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS ONE 2011; 6:e19881.
25. Menoret A, McAleer JP, Ngoi SM, et al. The oxazolidinone derivative locostatin induces cytokine appeasement. J Immunol 2009; 183:7489-7496.
26. Barre O, Solioz M. Improved protocol for chromatofocusing on the ProteomeLab PF2D. Proteomics 2006; 6:5096-5098.
27. Menoret A, Bell G. Purification of multiple heat shock proteins from a single tumor sample. J Immunol Methods 2000; 237:119-130.
28. Park JW, Choi YJ, Jang MA, et al. Chemopreventive agent resveratrol, a natural product derived from grapes, reversibly inhibits progression through S and G2 phases of the cell cycle in U937 cells. Cancer Lett 2001; 163:43-49.
29. Kim MY, Trudel LJ, Wogan GN. Apoptosis induced by capsaicin and resveratrol in colon carcinoma cells requires nitric oxide production and caspase activation. Anticancer Res 2009; 29:3733-3740.
30. Azios NG, Dharmawardhane SF. Resveratrol and estradiol exert disparate effects on cell migration, cell surface actin structures, and focal adhesion assembly in MDA-MB-231 human breast cancer cells. Neoplasia 2005; 7:128-140.
31. Azios NG, Krishnamoorthy L, Harris M, Cubano LA, Cammer M, Dharmawardhane SF. Estrogen and resveratrol regulate Rac and Cdc42 signaling to the actin cytoskeleton of metastatic breast cancer cells. Neoplasia 2007; 9:147-158.
32. Turano C, Coppari S, Altieri F, Ferraro A. Proteins of the PDI family: Unpredicted non-ER locations and functions. J Cell Physiol 2002; 193:154-163.
33. Wearsch PA, Peaper DR, Cresswell P. Essential glycan-dependent interactions optimize MHC class I peptide loading. Proc Natl Acad Sci USA 108:4950-4955.
34. Pressinotti NC, Klocker H, Schafer G, et al. Differential expression of apoptotic genes PDIA3 and MAP3K5 distinguishes between low- and high-risk prostate cancer. Mol Cancer 2009; 8:130.
35. Chay D, Cho H, Lim BJ, et al. ER-60 (PDIA3) is highly expressed in a newly established serous ovarian cancer cell line, YDOV-139. Int J Oncol 2010; 37:399-412.
36. Boyan BD, Chen J, Schwartz Z. Mechanism of Pdia3-dependent 1alpha, 25-dihydroxy vitamin D3 signaling in musculoskeletal cells. Steroids 77:892-896.
37. Navarro MS, Bachant J. RanBP2: A tumor suppressor with a new twist on TopoII, SUMO, and centromeres. Cancer Cell 2008; 13:293-295.
38. Dawlaty MM, Malureanu L, Jeganathan KB, et al. Resolution of sister centromeres requires RanBP2-mediated SUMOylation of topoisomerase IIalpha. Cell 2008; 133:103-115.
39. Murr R, Vaissiere T, Sawan C, Shukla V, Herceg Z. Orchestration of chromatin-based processes: Mind the TRRAP. Oncogene 2007; 26:5358-5372.
40. Hebert DN, Molinari M. In and out of the ER: Protein folding, quality control, degradation, and related human diseases. Physiol Rev 2007; 87:1377-1408.
41. de Sousa EM, Vermeulen L, Richel D, Medema JP. Targeting Wnt signaling in colon cancer stem cells. Clin Cancer Res 17:647-653.
42. Najdi R, Holcombe RF, Waterman ML. Wnt signaling and colon carcinogenesis: Beyond APC. J Carcinog 10:5.
43. Vergara D, Simeone P, Toraldo D, et al. Resveratrol downregulates Akt/GSK and ERK signalling pathways in OVCAR-3 ovarian cancer cells. Mol Biosyst 8:1078-1087.
44. Roy SK, Chen Q, Fu J, Shankar S, Srivastava RK. Resveratrol inhibits growth of orthotopic pancreatic tumors through activation of FOXO transcription factors. PLoS ONE 6:e25166.
45. Ikonomou G, Samiotaki M, Panayotou G. Proteomic methodologies and their application in colorectal cancer research. Crit Rev Clin Lab Sci 2009; 46:319-342.
46. Ahmed N, Oliva K, Wang Y, Quinn M, Rice G. Proteomic profiling of proteins associated with urokinase plasminogen activator receptor in a colon cancer cell line using an antisense approach. Proteomics 2003; 3:288-298.
47. Chen AL, Soman KV, Rychahou PG, Luxon BA, Evers BM. Proteomic analysis of colonic myofibroblasts and effect on colon cancer cell proliferation. Surgery 2005; 138:382-390.
48. Lee SC, Chan J, Clement MV, Pervaiz S. Functional proteomics of resveratrol-induced colon cancer cell apoptosis: Caspase-6-mediated cleavage of lamin A is a major signaling loop. Proteomics 2006; 6:2386-2394.
49. Lin KH, Hsiao G, Shih CM, Chou DS, Sheu JR. Mechanisms of resveratrol-induced platelet apoptosis. Cardiovasc Res 2009; 83:575-585.
50. Chen HB, Chan YT, Hung AC, Tsai YC, Sun SH. Elucidation of ATP-stimulated stress protein expression of RBA-2 type-2 astrocytes: ATP potentiate HSP60 and Cu/Zn SOD expression and stimulates pI shift of peroxiredoxin II. J Cell Biochem 2006; 97:314-326.
51. Dunn AY, Melville MW, Frydman J. Review: Cellular substrates of the eukaryotic chaperonin TRiC/CCT. J Struct Biol 2001; 135:176-184.
52. Tikoo K, Singh K, Kabra D, Sharma V, Gaikwad A. Change in histone H3 phosphorylation, MAP kinase p38, SIR 2 and p53 expression by resveratrol in preventing streptozotocin induced type I diabetic nephropathy. Free Radic Res 2008; 42:397-404.
53. Alkhalaf M. Resveratrol-induced growth inhibition in MDA-MB-231 breast cancer cells is associated with mitogen-activated protein kinase signaling and protein translation. Eur J Cancer Prev 2007; 16:334-341.
54. Jiang H, Shang X, Wu H, et al. Resveratrol downregulates PI3K/Akt/mTOR signaling pathways in human U251 glioma cells. J Exp Ther Oncol 2009; 8:25-33.
55. Kita K, Okumura N, Takao T, et al. Evidence for phosphorylation of rat liver glucose-regulated protein 58, GRP58/ERp57/ER-60, induced by fasting and leptin. FEBS Lett 2006; 580:199-205.
56. Tokutomi Y, Araki N, Kataoka K, Yamamoto E, Kim-Mitsuyama S. Oxidation of Prx2 and phosphorylation of GRP58 by angiotensin II in human coronary smooth muscle cells identified by 2D-DIGE analysis. Biochem Biophys Res Commun 2007; 364:822-830.
57. Bernardini M, Lee CH, Beheshti B, et al. High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer. Neoplasia 2005; 7:603-613.
58. Krynetskaia NF, Phadke MS, Jadhav SH, Krynetskiy EY. Chromatin-associated proteins HMGB1/2 and PDIA3 trigger cellular response to chemotherapy-induced DNA damage. Mol Cancer Ther 2009; 8:864-872.
59. Grillo C, D'Ambrosio C, Consalvi V, et al. DNA-binding activity of the ERp57 C-terminal domain is related to a redox-dependent conformational change. J Biol Chem 2007; 282:10299-10310.
60. Krynetski EY, Krynetskaia NF, Bianchi ME, Evans WE. A nuclear protein complex containing high mobility group proteins B1 and B2, heat shock cognate protein 70, ERp60, and glyceraldehyde-3-phosphate dehydrogenase is involved in the cytotoxic response to DNA modified by incorporation of anticancer nucleoside analogues. Cancer Res 2003; 63:100-106.
61. Grillo C, D'Ambrosio C, Scaloni A, et al. Cooperative activity of Ref-1/APE and ERp57 in reductive activation of transcription factors. Free Radic Biol Med 2006; 41:1113-1123.
62. Jayaraman L, Murthy KG, Zhu C, Curran T, Xanthoudakis S, Prives C. Identification of redox/repair protein Ref-1 as a potent activator of p53. Genes Dev 1997; 11:558-570.
63. Coe H, Michalak M. ERp57, a multifunctional endoplasmic reticulum resident oxidoreductase. Int J Biochem Cell Biol 2010; 42:796-799.
64. Zhu L, Santos NC, Kim KH. Disulfide isomerase glucose-regulated protein 58 is required for the nuclear localization and degradation of retinoic acid receptor alpha. Reproduction 139:717-731.
65. Herceg Z, Hulla W, Gell D, et al. Disruption of Trrap causes early embryonic lethality and defects in cell cycle progression. Nat Genet 2001; 29:206-211.
66. Benjamin JM, Nelson WJ. Bench to bedside and back again: Molecular mechanisms of alpha-catenin function and roles in tumorigenesis. Semin Cancer Biol 2008; 18:53-64.
67. Lien WH, Klezovitch O, Fernandez TE, Delrow J, Vasioukhin V. alphaE-catenin controls cerebral cortical size by regulating the hedgehog signaling pathway. Science 2006; 311:1609-1612.
68. Nemade RV, Bierie B, Nozawa M, et al. Biogenesis and function of mouse mammary epithelium depends on the presence of functional alpha-catenin. Mech Dev 2004; 121:91-99.